Cargando…

Market access pathways for cell therapies in France

INTRODUCTION AND OBJECTIVE: Cell therapies can be classified into three main categories of products: advanced therapy medicinal products (ATMPs), ATMPs prepared on a non-routine basis (hospital exemptions), and minimally manipulated cells. Despite the benefits that cell therapies can bring to patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rémuzat, Cécile, Toumi, Mondher, Jørgensen, Jesper, Kefalas, Panos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Co-Action Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802688/ https://www.ncbi.nlm.nih.gov/pubmed/27123176 http://dx.doi.org/10.3402/jmahp.v3.29094

Ejemplares similares

New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
por: Rémuzat, Cécile, et al.
Publicado: (2013)

New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry
por: Rémuzat, Cécile, et al.
Publicado: (2013)

Reimbursement of licensed cell and gene therapies across the major European healthcare markets
por: Jørgensen, Jesper, et al.
Publicado: (2015)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)

Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions
por: Frybourg, Sandrine, et al.
Publicado: (2015)

Key drivers for market penetration of biosimilars in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2017)

Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
por: Jørgensen, Jesper, et al.
Publicado: (2017)

Value added medicines: what value repurposed medicines might bring to society?
por: Toumi, Mondher, et al.
Publicado: (2016)

Advanced therapy medicinal products: current and future perspectives
por: Hanna, Eve, et al.
Publicado: (2016)

Gene therapies development: slow progress and promising prospect
por: Hanna, Eve, et al.
Publicado: (2017)

Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials
por: Hanna, Eve, et al.
Publicado: (2016)

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications
por: Murteira, Susana, et al.
Publicado: (2014)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
por: Jørgensen, Jesper, et al.
Publicado: (2018)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

The Market Access Society launches a new journal
por: Toumi, Mondher
Publicado: (2013)

Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching
por: Jørgensen, Jesper, et al.
Publicado: (2019)

Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
por: Jørgensen, Jesper, et al.
Publicado: (2020)

Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
por: Jarosławski, Szymon, et al.
Publicado: (2011)

A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments
por: Massetti, Marc, et al.
Publicado: (2015)

A price comparison of recently launched proprietary pharmaceuticals in the UK and the US
por: Jørgensen, Jesper, et al.
Publicado: (2016)

Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
por: Jørgensen, Jesper, et al.
Publicado: (2019)

Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey
por: Angermeyer, Matthias C, et al.
Publicado: (2013)

Overview of external reference pricing systems in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2015)

Supply-side and demand-side policies for biosimilars: an overview in 10 European member states
por: Rémuzat, Cécile, et al.
Publicado: (2017)

Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access
por: Driscoll, Dawn, et al.
Publicado: (2017)

French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends
por: Chouaid, Christos, et al.
Publicado: (2016)

Pharmaceutical expenditure forecast model to support health policy decision making
por: Rémuzat, Cécile, et al.
Publicado: (2014)

EU pharmaceutical expenditure forecast
por: Urbinati, Duccio, et al.
Publicado: (2014)

Novel methodology for pharmaceutical expenditure forecast
por: Vataire, Anne-Lise, et al.
Publicado: (2014)

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
por: Kefalas, Panos, et al.
Publicado: (2018)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

Determinants of orphan drugs prices in France: a regression analysis
por: Korchagina, Daria, et al.
Publicado: (2017)

Economic and health implications from earlier detection of HIV infection in the United Kingdom
por: Zah, Vladimir, et al.
Publicado: (2016)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
por: Bowrin, Kevin, et al.
Publicado: (2020)

Benefits of probabilistic sensitivity analysis – a review of NICE decisions
por: Adalsteinsson, Erpur, et al.
Publicado: (2013)

A prospective study of health care resource utilisation and selected costs of schizophrenia in France
por: Sarlon, Emmanuelle, et al.
Publicado: (2012)

Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
por: Hawken, Natalia, et al.
Publicado: (2017)

Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram
por: Llorca, Pierre-Michel, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_et37ajnqdcgj2ukp9vts29on4l